113 related articles for article (PubMed ID: 2215058)
41. High antibody levels to the mycobacterial fibronectin-binding antigen of 30-31 kD in tuberculosis and lepromatous leprosy.
Espitia C; Sciutto E; Bottasso O; González-Amaro R; Hernández-Pando R; Mancilla R
Clin Exp Immunol; 1992 Mar; 87(3):362-7. PubMed ID: 1371953
[TBL] [Abstract][Full Text] [Related]
42. Leprosy patients with lepromatous disease have an up-regulated IL-8 response that is unlinked to TNF-alpha responses.
Hasan Z; Mahmood A; Zafar S; Khan AA; Hussain R
Int J Lepr Other Mycobact Dis; 2004 Mar; 72(1):35-44. PubMed ID: 15217317
[TBL] [Abstract][Full Text] [Related]
43. Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report.
Zaheer SA; Suresh NR; Kar HK; Sharma AK; Mukherjee A; Mukherjee R; Talwar GP
Lepr Rev; 1991 Sep; 62(3):297-302. PubMed ID: 1795588
[TBL] [Abstract][Full Text] [Related]
44. Restoration of proliferative response to M. leprae antigens in lepromatous T cells against candidate antileprosy vaccines.
Mustafa AS
Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):257-67. PubMed ID: 8862259
[TBL] [Abstract][Full Text] [Related]
45. Reactions in borderline leprosy.
Ramu G; Desikan KV
Indian J Lepr; 2002; 74(2):115-28. PubMed ID: 12708730
[TBL] [Abstract][Full Text] [Related]
46. Serological monitoring of previously treated lepromatous patients during a course of multiple immunotherapy treatments with heat-killed Mycobacterium leprae and BCG.
Douglas JT; Hirsch DS; Fajardo TT; Guido LS; Klatser PR
Clin Exp Immunol; 1990 Dec; 82(3):567-73. PubMed ID: 2265493
[TBL] [Abstract][Full Text] [Related]
47. HLA-DQ molecules and the control of Mycobacterium leprae-specific T cell nonresponsiveness in lepromatous leprosy patients.
Ottenhoff TH; Walford C; Nishimura Y; Reddy NB; Sasazuki T
Eur J Immunol; 1990 Oct; 20(10):2347-50. PubMed ID: 1700754
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of the lepromin test--further information on the subject.
Dharmendra
Indian J Lepr; 1989 Jul; 61(3):387-90. PubMed ID: 2768886
[No Abstract] [Full Text] [Related]
49. A recessive major gene controls the mitsuda reaction in a region endemic for leprosy.
Ranque B; Alcais A; Thuc NV; Woynard S; Thai VH; Huong NT; Ba NN; Khoa PX; Schurr E; Abel L
J Infect Dis; 2005 Oct; 192(8):1475-82. PubMed ID: 16170767
[TBL] [Abstract][Full Text] [Related]
50. Interleukin-1 beta production by monocytes from leprosy patients.
Choi IH; Shin JS; Park SK; Cho SN; Kim JD; Kim SJ
Yonsei Med J; 1990 Dec; 31(4):301-7. PubMed ID: 2077754
[TBL] [Abstract][Full Text] [Related]
51. Leprosy patients with lepromatous disease recognize cross-reactive T cell epitopes in the Mycobacterium leprae 10-kD antigen.
Hussain R; Dockrell HM; Shahid F; Zafar S; Chiang TJ
Clin Exp Immunol; 1998 Nov; 114(2):204-9. PubMed ID: 9822277
[TBL] [Abstract][Full Text] [Related]
52. Lepromatous leprosy treated with combined chemotherapy and immunotherapy (injection BCG): three case reports.
Lakshmi C; Srinivas CR
Int J Dermatol; 2014 Jan; 53(1):61-5. PubMed ID: 23675902
[TBL] [Abstract][Full Text] [Related]
53. Reversal reactions in lepromatous leprosy following transfer factor therapy.
Hastings RC; Job CK
Am J Trop Med Hyg; 1978 Sep; 27(5):995-1004. PubMed ID: 717642
[TBL] [Abstract][Full Text] [Related]
54. Immunological cytokine correlates of protective immunity and pathogenesis in leprosy.
Lima MC; Pereira GM; Rumjanek FD; Gomes HM; Duppre N; Sampaio EP; Alvim IM; Nery JA; Sarno EN; Pessolani MC
Scand J Immunol; 2000 Apr; 51(4):419-28. PubMed ID: 10736116
[TBL] [Abstract][Full Text] [Related]
55. Lepromin-induced suppressor cells in lepromatous leprosy.
Nelson EE; Wong L; Uyemura K; Rea TH; Modlin RL
Cell Immunol; 1987 Jan; 104(1):99-104. PubMed ID: 2948676
[TBL] [Abstract][Full Text] [Related]
56. Effects of chemotherapy on antibody levels directed against PGL-I and 85A and 85B protein antigens in lepromatous patients.
Drowart A; Chanteau S; Huygen K; De Cock M; Cartel JL; De Bruyn J; Launois P; Yernault JC; Van Vooren JP
Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):29-34. PubMed ID: 8326178
[TBL] [Abstract][Full Text] [Related]
57. T-cell stimulation with purified mycobacterial antigens in patients and healthy subjects infected with Mycobacterium leprae: secreted antigen 85 is another immunodominant antigen.
Launois P; Niang MN; Sarthou JL; Rivier F; Drowart A; Van Vooren JP; Millan J; Huygen K
Scand J Immunol; 1993 Aug; 38(2):167-76. PubMed ID: 8346416
[TBL] [Abstract][Full Text] [Related]
58. The immunobiology of leprosy.
Kaplan G; Cohn ZA
Int Rev Exp Pathol; 1986; 28():45-78. PubMed ID: 3516911
[TBL] [Abstract][Full Text] [Related]
59. Early and late reactions in tuberculoid and lepromatous leprosy patients with lepromins from Mycobacterium leprae and five selected cultivable mycobacteria.
Mustafa AS; Talwar GP
Lepr India; 1978 Oct; 50(4):566-71. PubMed ID: 374875
[No Abstract] [Full Text] [Related]
60. Assessment of the immune deficit in leprosy patients and the effect of recombinant IL-2 in vitro.
Locniskar M; McEniry DW; Mudd DW; Rose P; Lucas DC; Larrick J; McAdam KP
Int J Lepr Other Mycobact Dis; 1987 Jun; 55(2):249-60. PubMed ID: 3298472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
